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normal admission electrocardiogram (all p  ! 0.05). After ad-
justing for length of stay, hospital complications associated 
with arrhythmia included myocardial ischemia, hyperglyce-
mia, and herniation (all p  ! 0.05). Arrhythmia was associated 
with an excess ICU stay of 5 days (p = 0.002). After adjusting 
for other predictors of outcome, arrhythmia was associated 
with an increased risk of death (adjusted OR 8.0, 95% confi-
dence interval 1.9–34.0, p = 0.005), and death or severe dis-
ability (adjusted OR 6.9, 95% confidence interval 1.5–32.0,
p = 0.014).  Conclusions: Clinically important arrhythmias, 
most often atrial fibrillation or flutter, occurred in 4% of SAH 
patients. Arrhythmias are associated with an increased risk 
of cardiovascular comorbidity, prolonged hospital stay and 
poor outcome or death after SAH, after adjusting for other 
predictors of poor outcome.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Cardiac abnormalities following subarachnoid hem-
orrhage (SAH) are well described. Electrocardiogram 
(ECG) changes, including P wave abnormalities, pro-
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 Abstract 
 Objective: Serious cardiac arrhythmias have been described 
in approximately 5% of patients after subarachnoid hemor-
rhage (SAH). The aim of this study was to identify the fre-
quency, risk factors and clinical impact of cardiac arrhythmia 
after SAH.  Methods: We prospectively studied 580 sponta-
neous SAH patients and identified risk factors and complica-
tions associated with the development of clinically signifi-
cant arrhythmia. Multiple logistic regression analysis was 
used to calculate adjusted odds ratios for the effect of ar-
rhythmia on hospital complications and 3-month outcome, 
as measured by the modified Rankin Scale, after controlling 
for age, neurological grade, APACHE-2 physiologic subscore, 
brain herniation and aneurysm size.  Results: Arrhythmia oc-
curred in 4.3% (n = 25) of patients. Atrial fibrillation and flut-
ter were the most common arrhythmias, occurring in 76%
(n = 19) of these patients. Admission predictors of cardiac ar-
rhythmia included older age, history of arrhythmia and ab-
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longed QTc interval, ST segment and T-wave changes, oc-
cur in over 50% of patients  [1–3] , often in the first few 
days after SAH onset, and are associated with poor neu-
rologic grade on admission  [4] .
 Between 50 and 100% of patients experience cardiac 
rhythm disturbances during the acute phase of SAH. The 
majority of these abnormalities are benign, with sinus 
tachycardia, sinus bradycardia, and premature atrial and 
ventricular beats being the most common. Only 1–4% of 
patients experience a clinically significant arrhythmia, 
such as ventricular tachycardia or atrial tachyarrhyth-
mias  [5–10] . Predictors of serious cardiac arrhythmias re-
main poorly defined, and their impact on clinical out-
come is unknown. In this study we sought to identify the 
prevalence, risk factors, hospital complications associat-
ed with arrhythmia and impact on long-term outcome of 
cardiac arrhythmias after SAH. We hypothesized that, 
though uncommon, clinically significant arrhythmias 
are associated with increased hospital complications, 
prolonged length of stay and worse outcome.
 Methods 
 Patient Population 
 The Columbia University SAH Outcomes Project prospective-
ly enrolled 580 consecutive patients with spontaneous SAH ad-
mitted to the Neurologic Intensive Care Unit between July 1, 1996 
and May 1, 2002. The diagnosis of SAH was established on the 
basis of admission computed tomography (CT) or by xanthochro-
mia of the cerebrospinal fluid. Both aneurysmal and non-aneu-
rysmal cases of spontaneous SAH were included in this analysis. 
Exclusion criteria included: secondary SAH from trauma, arte-
riovenous malformation or other causes; age  ! 18 years; admis-
sion  1 14 days after SAH onset, or no ECG available for review. 
 Clinical Management 
 The management of SAH patients at our institution has been 
described in detail previously  [11, 12] . Phenytoin was adminis-
tered for a median of 7 days and levels were checked regularly to 
maintain a serum concentration between 10 and 20 mg/dl  [13] . 
All patients received 0.9% normal saline at 1 mg/kg/h and supple-
mental 5% albumen was administered as needed to maintain nor-
movolemia (central venous pressure 5–8 mm Hg). Patients who 
developed symptomatic vasospasm, defined as neurologic dete-
rioration not explained by other causes, were treated with vaso-
pressors (either phenylephrine or norepinephrine) to maintain a 
systolic blood pressure between 160 and 220 mm Hg, adjusted to 
clinical response.
 Clinical and Radiographic Assessment 
 Admission clinical status was evaluated with the Hunt-Hess 
scale and the Acute Physiology and Chronic Health Evaluation 
(APACHE)-2 physiologic subscore (calculated by subtracted 
Glasgow Coma Score from the APACHE-2 score). We defined hy-
potension as a systolic blood pressure  ^  90 mm Hg, pulmonary 
edema was defined as the presence of characteristic radiographic 
infiltrates in the setting of hypoxia, and we considered myocar-
dial infarction/ischemia (MI) to be evidence of cardiac injury 
(based on ECG, troponin and echocardiographic data judged not 
to be secondary to neurogenic injury by a study team of physicians 
in weekly conference). We examined medications, procedures, el-
evated volume status (defined by central venous pressure  6 8 mm 
Hg, and  6 1 liter net volume intake in 24 h prior to arrhythmia 
onset) and electrolyte levels within 24 h of arrhythmia onset. Ab-
normal values were defined by our laboratory’s lower limit of nor-
mal, including a potassium  ! 3.6 mg/dl, magnesium  ! 1.5 mg/dl, 
phosphorus  ! 2.5 mg/dl and calcium  ! 8.4 mg/dl or ionized cal-
cium  ! 1.12 mg/dl. An abnormal troponin level was defined as 
 1 0.2 ng/ml. Total phenytoin levels within 24 h of development of 
arrhythmia were recorded, as were average phenytoin levels over 
the course of hospitalization. 
 Cardiac Monitoring 
 All patients underwent continuous cardiac rhythm monitor-
ing while in the neuro-ICU. ECGs were routinely obtained at 
 admission and then periodically, as determined by the treating 
physician. Serial troponin levels and echocardiography were per-
formed when ECGs were abnormal, in patients with a prior his-
tory of cardiac disease, or in the setting of cardiovascular symp-
toms such as chest pain, hypotension, or pulmonary edema.
Ejection fraction (EF) was assessed by transthoracic (and/or 
transesophageal) echocardiography, and was dichotomized as 
normal (EF  6 50%) versus abnormal.
 Blinded Cardiac Assessment 
 Serial ECGs for all patients coded with arrhythmia by the 
treating physician were independently assessed by a board-certi-
fied cardiologist (DS), blinded to the clinical characteristics and 
outcome status of the patient. Patients coded as experiencing an 
arrhythmia, but who did not have ECGs available for review, were 
excluded from the present analysis. Admission ECGs and all fol-
low up ECGs were assessed. We defined clinically significant ar-
rhythmia as any rhythm disturbance other than sinus tachycar-
dia, sinus bradycardia, or sinus rhythm with premature atrial or 
ventricular complexes. 
 Outcome Measures 
 Survival and functional outcome was assessed at 3 months us-
ing the modified Rankin Scale (mRS; 0 = full recovery, 6 = death); 
poor outcome was defined as severe disability or death (mRS 
score 4–6). Median excess ICU and hospital length of stay (LOS) 
were calculated by comparing the median LOS of patients with 
arrhythmia to those without. 
 Statistical Analysis 
 Continuous variables were dichotomized based on clinical 
cut-points or median values. The association of arrhythmia with 
candidate demographic and clinical variables was assessed in a 
univariate analysis using binary logistic regression. Variables 
found to be significant on univariate analysis were then entered 
by hand into a multiple logistic regression model based on clinical 
relevance of each variable. A multivariate model addressing the 
association of arrhythmia and in-hospital complications was con-
structed, adjusting for hospital LOS. Finally, a multivariate mod-
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el examining the effect of arrhythmia on 3-month outcome was 
created, after controlling for other predictors of outcome in-
cluding age, Hunt-Hess grade, aneurysm size, herniation and 
APACHE-2 physiologic subscore  [11, 14] . Elevated intracranial 
pressure and low EF did not predict outcome on univariate anal-
ysis and were not included in the multivariate model. The variable 
for clinically significant arrhythmias was added individually to 
this model to calculate adjusted odds ratios for the strength of as-
sociation of arrhythmia with ‘death’ and ‘severe disability or 
death’ (mRS 4–6). Tests for interactions were performed for all 
significant variables in the multivariable models. Significance 
was set at p  ! 0.05 for all analyses.
 Results 
 Of 580 SAH patients enrolled in our database, 8% (n = 
46) were coded as having an arrhythmia sometime dur-
ing their hospital stay. Ten patients did not have ECGs 
available for review. After excluding patients with sinus 
bradycardia, sinus tachycardia or sinus rhythm with or 
without premature ventricular or apical complexes, 4.3% 
(n = 25) of patients in the cohort had a verified clinically 
significant arrhythmia. Among this group the mean age 
was 53 years (range 20–89), and 68% were female. The 
majority of patients underwent aneurysm clipping (81%). 
The type of aneurysm repair (surgical clipping vs. endo-
vascular coiling) was not associated with an increased 
risk of arrhythmia. The median number of different ar-
rhythmias per patient was 1 (range 1–4) and the median 
number of days of arrhythmia per patient was 2.5 (range 
1–41). Arrhythmia developed a median of 3 days after 
SAH onset (range 0–30). The most common type of ar-
rhythmia was atrial fibrillation or flutter (76%) and only 
16% of patients experienced a ventricular arrhythmia ( ta-
ble 1 ). 
 Admission predictors for arrhythmia were examined 
( table 2 ). An abnormal ECG (such as left or right axis de-
viation, PR segment abnormality, ST segment elevation 
or depression, T-wave abnormality, QTc prolongation or 
bundle branch block) at admission was found in 92% of 
patients who developed an arrhythmia and independent-
ly predicted arrhythmia [adjusted OR 9.4, 95% confi-
dence interval (CI) 2.2–40.5, p = 0.002]. On the cardiol-
ogist’s review of admission ECGs among arrhythmia pa-
tients, a prolonged QTc  1 500 ms was seen in 16% of 
patients, ST segment abnormalities were seen in 67% and 
T-wave inversion was seen in 25%. Though a cardiac his-
tory of coronary artery disease, angina or MI were asso-
ciated with the development of a clinically significant ar-
rhythmia during hospitalization on univariate analysis, 
only a history of arrhythmia remained an independent 
predictor on multivariate analysis (adjusted OR 9.1, 95% 
CI 2.7–30.7, p  ! 0.001). All 5 patients (20%) with a his-
tory of arrhythmia had atrial fibrillation in the past, but 
2 of these 5 developed other arrhythmias including atrial 
flutter, second degree heart block and junctional 
rhythm. 
 Clinical treatments associated with the development 
of arrhythmia were recorded. Among those with arrhyth-
mia, 24% received hypertensive, hypervolemia therapy 
(HHT) to treat symptomatic vasospasm, 48% received an 
intravenous pressor and 4% received hypertonic saline 
prior to the time the arrhythmia developed. Twenty per-
cent of patients with arrhythmia were in volume overload 
at the time of arrhythmia onset ( table 3 ). There was no 
significant association between the development of ar-
rhythmia and HHT. Mean phenytoin levels were not sig-
nificantly associated with arrhythmia. The most com-
mon electrolyte abnormality was hypokalemia, which 
occurred in 28% of arrhythmia patients. An elevated tro-
ponin or CK-MB occurred in 24% of patients. 
 Recurrent arrhythmia occurred in 72% of our cohort. 
Despite treatment, 44% continued to have arrhythmias. 
The most common arrhythmias to recur were atrial fi-
brillation or flutter (56%) and ventricular arrhythmias 
(11%). Treatments included digoxin in 10 patients (40%), 
diltiazem in 7 patients (28%), metoprolol in 4 patients 
(16%), amiodarone in 4 patients (16%), procainamide in 1 
patient (4%), lidocaine in 1 patient (4%) and atropine in 1 
patient (4%).
 Several medical complications were significantly as-
sociated with arrhythmia after adjusting for hospital 
Table 1. Types of arrhythmia among 25 patients with SAH
Type of arrhythmia n %
Atrial fibrillation or atrial flutter 19 76
Junctional rhythm 4 16
Pauses 4 16
Supraventricular tachycardia 3 12
Asystole 3 12
Bigeminy 2 8
Ectopic atrial pacemaker 1 4
Multifocal atrial tachycardia 1 4
Non-sustained ventricular tachycardia 1 4
Sustained ventricular tachycardia 1 4
2nd degree heart block Mobitz I 1 4
2nd degree heart block Mobitz II 1 4
3rd degree heart block 1 4
Torsade de pointes 0 0
Ventricular fibrillation 0 0
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LOS, these included hyperglycemia, brainstem compres-
sion from herniation and MI ( table 4 ). Of those who de-
veloped MI, the mean troponin level was 9.2 ng/ml (range 
0–22.2 ng/ml). Three patients with MI had normal trans-
thoracic echocardiography and 3 had mild to moderate 
reductions in EF with anterior-septal or septal hypoki-
nesis. A transthoracic or transesophageal echocardio-
gram was performed in 38% of the entire cohort and in 
76% of those who developed an arrhythmia. Of those 
who underwent echocardiography, an EF  ! 50% was seen 
in 21% of the entire cohort and in 11% of those who de-
veloped an arrhythmia. There was no significant asso-
ciation between an EF  ! 50% and arrhythmia (OR 0.4, 
95% CI 0.1–1.9, p = 0.265). Similarly, EF  ! 50% was not a 
significant predictor of outcome. Four of the 25 arrhyth-
mia patients (16%) experienced a cardiac arrest at some 
point during their hospitalization. Though none of the 
patients who arrested died in the hospital, 3 (75%) were 
dead at 3 months and 1 was severely disabled. No pa-
tients with arrhythmia experienced renal failure and 
there was no significant association of arrhythmia with 
blood stream infection or sepsis. The only neurologic 
complication associated with arrhythmia was herniation 
( table 4 ).
 Sixteen of 25 (64%) patients who experienced an ar-
rhythmia were dead at 3 months and 1 was severely dis-
abled. Of all patients with arrhythmia who died, 50% 
died of direct effects of the initial SAH, 17% died of med-
ical complications (including arrhythmia), 17% died of 
cerebral edema, 8% died of rebleeding, and 8% died of 
various other causes. After controlling for age, Hunt-
Hess grade, clinical herniation, aneurysm size, and 
APACHE-2 physiologic subscore, clinically significant 
arrhythmias remained independently predictive of death 
(adjusted OR 8.0, 95% CI 1.9–34.0, p = 0.005) and severe 
disability or death (mRS 4–6; adjusted OR 6.9, 95% CI 





OR (95% CI) p
n % n %
Demographics
Age >53 years 300 52 21 84 5.1 (1.7–15.2) 0.003*
Gender (female) 392 68 19 76 1.5 (0.6–3.9) 0.374
Race (non-white) 284 49 6 24 0.3 (0.1–0.8) 0.015
Medical history
Hypertension 266 46 19 76 5.5 (1.8–16.4) 0.002
Coronary artery disease/angina 31 5 3 12 3.5 (1.0–12.9) 0.057
Arrhythmia 18 3 4 16 9.1 (2.7–30.7) <0.001*
CHF 12 2 1 4 2.7 (0.3–22.3) 0.351
Myocardial infarction 22 4 3 12 4.9 (1.3–18.4) 0.017
Thyroid dysfunction 32 6 1 4 0.9 (0.1–7.2) 0.946
Admission radiographic data
SAH sum score ≥15 225 38 20 80 5.0 (1.7–14.8) 0.004
IVH present  281 49 19 76 3.9 (1.4–10.5) 0.008
ICH present 96 17 5 20 1.3 (0.5–3.5) 0.650
Aneurysm size ≥10 mm 117 20 8 32 2.2 (0.9–5.4) 0.093
Admission clinical data
Hunt-Hess score 337 58 19 76 1.4 (1.0–1.9) 0.033
Loss of consciousness 224 39 16 64 4.3 (1.7–11.2) 0.003
Seizure at ictus 5 9 9 16 2.4 (0.8–7.4) 0.132
APACHE-2 subscore ≥5 303 52 18 72 2.6 (1.0–6.8) 0.045
Abnormal admission ECG 320 55 23 92 9.4 (2.2–40.5) 0.002*
* p value significant on multivariate analysis. CHF = Congestive heart failure; IVH = intraventricular hemorrhage; ICH = intra-
cerebral hemorrhage.
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1.5–32.0, p = 0.014) at 3 months ( table 5 ). We examined 
the effect of subtypes of arrhythmia (i.e. atrial or ven-
tricular arrhythmias) on outcome, but did not find any 
significant associations.
 A significantly longer ICU LOS was associated with 
the occurrence of a clinically significant arrhythmia. The 
median ICU LOS in those with arrhythmia was 13 days, 
compared to 8 days in the patients without arrhythmia 
(p = 0.002); the median hospital LOS in those with ar-
rhythmia was 15 days, compared to 13 days in the pa-
tients without arrhythmia (p = 0.132).
 Discussion 
 In this inception cohort study we were able to demon-
strate that arrhythmia following SAH is associated with 
a high rate of mortality and predicts poor functional out-
come at 3 months, after adjusting for neurological grade 
and severity of clinical illness (APACHE-2 physiological 
subscore), age, herniation and aneurysm size. Our study 
is the first, to our knowledge, to show that clinically sig-
Table 3. Hospital risk factors among arrhythmia cohort
n %
Medications
Intravenous pressor 12 48
Hypertonic saline 1 4
Elevated total phenytoin level >20 mg/dl 1 4
Diuretic 6 24
Albuterol 4 16
Nicotine patch 1 4
Electrolyte and lab abnormalities
Potassium <3.6 mg/dl 7 28
Phosphorus <2.5 mg/dl 4 16
Magnesium <1.5 mg/dl 0 0
Calcium <8.4 mg/dl or 
ionized calcium <1.12 mg/dl 4 16
Elevated troponin or CK-MB 6 24
Volume status
Central venous pressure ≥8 mm Hg 8 32
>1 liter net volume input in previous 24 h 6 24
Procedures/therapies
Central line 9 36
Pulmonary artery catheter 2 8
Therapeutic hypothermia 0 0
Table 4. Hospital complications associated with arrhythmia, adjusted for hospital length of stay
Entire cohort Arrhythmia group Adjusted OR 
(95% CI)
Adjusted
pn % n %
Medical complication
Ejection fraction <50% 46 8 3 12 0.4 (0.1–1.9) 0.285
Cardiac arrest 57 10 4 16 2.0 (0.6–6.0) 0.238
Blood stream infection 48 8 3 12 1.4 (0.4–4.8) 0.639
Hypotensiona 105 18 8 32 2.2 (0.9–5.2) 0.082
Anemia requiring transfusion 209 36 14 56 2.1 (0.9–5.1) 0.099
Fever >38.3°C 310 54 19 76 2.4 (0.8–6.8) 0.089
DVT 23 4 2 8 1.7 (0.4–7.9) 0.502
Hyperglycemia >11.1 mmol/l 174 30 13 52 2.7 (1.2–6.1) 0.020*
MI/Ischemia 35 6 7 28 6.7 (2.6–17.4) <0.001*
Pulmonary edema 82 14 7 28 2.2 (0.8–5.6) 0.110
Neurologic complication 
Symptomatic vasospasm 95 16 7 28 1.7 (0.7–4.3) 0.269
Herniation 89 15 8 32 3.4 (1.4–8.3) 0.008*
Cerebral infarction 208 36 11 44 1.2 (0.5–2.9) 0.610
Seizures 31 5 2 8 1.3 (0.3–6.0) 0.726
Aneurysm rebleed 58 10 1 8 0.8 (0.2–3.4) 0.732
Adjusted for ICU LOS. MI = Myocardial infarction; DVT = deep vein thrombosis. 
* p value significant on multivariate analysis.
a Defined as sustained systolic blood pressure <90 mm Hg.
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nificant arrhythmias are predictive of mortality as well 
as disability after SAH. Previous studies have yielded 
conflicting results regarding the clinical importance of 
various cardiac abnormalities after SAH. Tachyarrhyth-
mias and cardiac ischemia have been related to poor out-
come after SAH, though this association was less robust 
after controlling for admission Glasgow Coma Scale 
score and Fisher grade  [1] . While ECG abnormalities 
were found to predict outcome in another study, this as-
sociation lost significance when a multivariate model 
was applied  [15] . Similarly, others have not been able to 
find a significant relationship between ECG abnormali-
ties and outcome after SAH, after controlling for estab-
lished predictors of poor outcome  [4, 16] . Elevated tro-
ponin was independently predictive of death or severe 
disability at 14 days after SAH in one study, but this ef-
fect was lost at 3 months  [17] . Though 50% of patients 
who died succumbed to the direct effects of the initial 
bleeding, 17% died of medical complications, including 
arrhythmia. 
 Though some studies have described rates of arrhyth-
mia after SAH of 30% and higher, these studies included 
patients with sinus bradycardia and tachycardia and pre-
mature atrial and ventricular complexes  [4, 6] . The rates 
of clinically significant arrhythmia, as defined in this pa-
per, are similar to those seen in the literature. We ob-
served a higher rate of atrial fibrillation and flutter than 
has been previously described in other SAH arrhythmia 
cohorts. While 76% of our group developed atrial fibril-
lation or flutter, this rhythm was observed in only 10% of 
SAH patients with arrhythmia in another study  [5] . In 
mixed ICU populations, clinically significant tachyar-
rhythmias occur in up to 20% of patients overall, with 
atrial fibrillation occurring most frequently  [18] . In our 
study, recurrent arrhythmias (particularly atrial fibrilla-
tion or flutter) were common despite treatment, suggest-
ing that more aggressive management of arrhythmia may 
be warranted. 
 Predictors for the development of arrhythmia in our 
cohort included older age, abnormal ECG at admission 
and a history of arrhythmia. Though worse neurologi-
cal grade and APACHE-2 physiologic subscores were 
significant risk factors for the development of arrhyth-
mia on univariate analysis, this effect was not sustained 
on multivariate analysis. Arrhythmia does not merely 
reflect degree of critical illness. Pre-existing cardiac 
disease was not independently associated with arrhyth-
mia, suggesting that a history of cardiac disease alone 
does not explain a predisposition to arrhythmia. Risk 
factors for tachyarrhythmias amongst critically ill sur-
gical ICU patients include sepsis, elevated CVP, acute 
renal failure, anemia requiring transfusion and poor 
APACHE-2 scores  [18–20] . We were unable to find any 
of these associations in our neurologically ill SAH pa-
tients  [19] .
 Neurologically ill patients differ from general critical-
ly ill patients in several ways. Elevated catecholamine lev-
els and hypothalamic dysfunction have been described in 
SAH patients compared with controls and have been as-
sociated with both ECG abnormalities and tachyarrhyth-
mias  [21–23] . Hyperglycemia, which can occur in re-
sponse to an acute catecholamine surge or generalized 
stress response following neurologic injury was noted to 
be associated with arrhythmia in our cohort  [14, 24, 25] . 
Some arrhythmias may be related, in part, to HHT ther-
apy used to treat symptomatic vasospasm, as both intra-
venous pressors and volume expansion, which are known 
risk factors for supraventricular tachyarrhythmias, were 
used frequently in the patients who developed arrhyth-
mia. We were unable to detect a significant relationship 
between HHT and arrhythmia, but this may be due to 
insufficient power. Though elevated phenytoin levels can 
Table 5. Adjusted outcomes at 3 months among SAH patients with clinically significant arrhythmia
Outcome at 3 months Entire cohort Arrhythmia group Adjusted OR
(95% CI)
Adjusted
pn % n %
Dead (mRS 6) 119 21 16 64 8.0 (1.9–34.0) 0.005*
Severely disabled or dead (mRS 4–6) 151 26 17 68 6.9 (1.5–32.0) 0.014*
Outcome adjusted for age, Hunt-Hess grade, aneurysm size, APACHE-2 physiologic subscore and brain herniation. mRS = Modi-
fied Rankin Scale. 
* p value significant on multivariate analysis. 
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be associated with arrhythmia, we did not observe this 
association in our cohort. 
 Interestingly, arrhythmia was significantly associated 
with brainstem compression from herniation. Increased 
ICP and physical compression of brainstem and hypo-
thalamic autonomic centers in herniating patients can 
trigger catecholamine responses that could instigate an 
arrhythmia. 
 The ICU LOS was significantly prolonged in patients 
who developed arrhythmia compared to the rest of the 
cohort. Though it is not possible to determine whether 
prolonged LOS predisposed patients to arrhythmia or if 
arrhythmia itself was causal, the fiscal implications of 
prolonged LOS are profound.
 There are several limitations to this study which should 
be mentioned. First, we only had echocardiographic data 
in 38% of our cohort. However, no other studies, to our 
knowledge, have examined EF and the occurrence of ar-
rhythmia after SAH; as such, we are the first to explore 
this relationship. We did not have complete time-locked 
data on IV pressor or hypertonic saline use in the cohort 
as a whole, and this limited our ability to compare the ef-
fects of these medications in those with arrhythmia and 
those without. We also did not have complete data on tro-
ponin levels.
 In summary, although clinically significant arrhyth-
mias are relatively uncommon after SAH, they are associ-
ated with a high mortality rate, and serious cardiac and 
neurological comorbidity. Older patients with a history 
of arrhythmia or an abnormal ECG on admission should 
undergo close cardiac monitoring, and the presence of 
rhythm disturbances should prompt aggressive measures 
to treat MI, maintain a normal cardiac rhythm and min-
imize autonomic stress, when present.
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